Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
A New CELMoD Contender: SUCCESSOR-2 Highlights Mezigdomide’s Potential in Myeloma | EHA 2026
HealthTreeDescription
In this video, we break down the SUCCESSOR-2 trial results evaluating mezigdomide plus dexamethasone in relapsed/refractory multiple myeloma. We review the latest efficacy and safety data presented at EHA 2026 and discuss what these findings could mean for patients with heavily pretreated, difficult-to-treat disease.
Mezigdomide is a next-generation cereblon modulator being studied as a potential option for patients who have exhausted multiple prior therapies. Watch for a clear summary of the key outcomes, clinical implications, and why these results matter in the evolving treatment landscape for multiple myeloma.
If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu
For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.